AKBA
- Akebia Therapeutics, Inc.
()
Overview
Company Summary
Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with kidney diseases. The company's primary focus is on the development of therapeutics to manage the complications associated with chronic kidney disease (CKD).
Akebia Therapeutics is primarily known for its leading investigational product, Vadadustat. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which aims to mimic the physiological response of the body to low oxygen levels. By doing so, Vadadustat stimulates the production of red blood cells, helping to address anemia, a prevalent complication in CKD patients.
Anemia is a result of decreased kidney function leading to reduced production of erythropoietin, a hormone that regulates red blood cell production. Vadadustat's innovative mechanism of action offers an alternative treatment to currently available erythropoiesis-stimulating agents (ESAs). This could potentially provide improved efficacy, safety, and convenience for patients, as Vadadustat is administered orally, whereas ESAs require injections.
Akebia Therapeutics conducts extensive clinical trials to evaluate the safety and efficacy of Vadadustat in various stages of CKD, including both non-dialysis-dependent CKD patients and those on dialysis. If successful, Vadadustat has the potential to become a new standard of care for managing anemia in CKD patients.
Besides Vadadustat, Akebia Therapeutics also explores other therapeutic candidates to address additional complications associated with kidney diseases. Their goal is to provide treatment options to improve the lives of patients suffering from CKD, offering innovative and patient-friendly solutions.
In summary, Akebia Therapeutics, Inc. is a biopharmaceutical company specializing in the development of innovative treatments for kidney diseases, with a primary focus on addressing anemia in chronic kidney disease patients using their lead investigational product, Vadadustat.